<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004562</url>
  </required_header>
  <id_info>
    <org_study_id>130</org_study_id>
    <secondary_id>U01HL062509-01A1</secondary_id>
    <nct_id>NCT00004562</nct_id>
  </id_info>
  <brief_title>Occluded Artery Trial (OAT)</brief_title>
  <acronym>OAT</acronym>
  <official_title>Occluded Artery Trial (OAT) - Randomized Comparative Effectiveness Trial of PCI and Medical Therapy Only Post MI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether opening an occluded infarcted artery 3-28
      days after an acute myocardial infarction in high-risk asymptomatic patients reduces the
      composite endpoint of mortality, recurrent myocardial infarction, and hospitalization for
      class IV congestive heart failure over an average 2.9-year follow-up with extended follow up
      for an average of six years. Long term follow-up of patients were completed in March 2010.
      Final collection of all regulatory documentation was completed June 2011.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      The benefits of establishing early coronary reperfusion in acute myocardial infarction (MI)
      have now been unequivocally established. However, current pharmacologic strategies fail to
      achieve effective reperfusion in 30 percent or more of patients, and many patients with
      occluded infarct arteries do not meet current criteria for use of these agents. Early
      angioplasty, an effective reperfusion method, is available to a small proportion of
      potentially eligible US acute MI patients. Hence a substantial number of acute MI patients
      pass the time when reperfusion therapy has any documented benefit (12 - 24 hours) with a
      persistently closed infarct vessel. Several lines of experimental and clinical evidence
      suggest that late reperfusion of these patients could provide clinically significant
      reductions in mortality and morbidity.

      DESIGN NARRATIVE:

      Multicenter, randomized, controlled. Patients at 217 clinical sites in the United States,
      Canada and Internationally were randomly allocated to two treatment arms over five years. One
      treatment consists of conventional medical management including aspirin, beta blockers,
      angiotensin converting enzyme (ACE) inhibitors, and risk factor modification. The other
      treatment consists of conventional medical therapy plus percutaneous coronary intervention
      and coronary stenting. Clinical outcomes will be compared using an intention-to-treat
      analysis. The primary composite endpoint is mortality, recurrent myocardial infarction, and
      hospitalization for NYHA Class IV congestive heart failure over a three year follow-up.
      Individual components of the study composite primary endpoint will be compared in the two
      treatment arms, as will the medical costs of the two treatments and the health-related
      quality of life. The cost-effectiveness of percutaneous revascularization will be assessed in
      the study population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1999</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients That Had a First Occurrence of the Primary End Point (Composite of Death From Any Cause, Nonfatal MI, or Class IV HF)</measure>
    <time_frame>Measured over a maximum 9-year follow-up period - 6 year median</time_frame>
    <description>Number of Patients with Events (death from any cause, nonfatal reinfarction, and hospitalization for New York Heart Association (NYHA) Class IV congestive heart failure). Events were centrally adjudicated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Secondary Outcomes (Safety Events)</measure>
    <time_frame>Measured over a maximum 9-year follow-up period - 6 year median</time_frame>
    <description>Number of Participants with Secondary Outcomes (death from any cause, nonfatal MI, class IV HF, cardiac death, occurrence of selected clinical outcomes including stroke, hospitalization for CHF, sustained ventricular tachycardia/ventricular fibrillation, ICD implantation, or the composite end point). Events were centrally adjudicated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2201</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Diseases</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Heart Failure, Congestive</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Optimal Medical Therapy Only (MED)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional medical management, including aspirin, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and risk factor modification</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Percutaneous Coronary Intervention (PCI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional medical management, including aspirin, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and risk factor modification, plus percutaneous coronary intervention and coronary stenting</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta adrenergic blockers</intervention_name>
    <description>Participants will receive beta adrenergic blockers.</description>
    <arm_group_label>Optimal Medical Therapy Only (MED)</arm_group_label>
    <arm_group_label>Percutaneous Coronary Intervention (PCI)</arm_group_label>
    <other_name>beta blockers</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Platelet inhibitors</intervention_name>
    <description>Participants will receive platelet inhibitors.</description>
    <arm_group_label>Optimal Medical Therapy Only (MED)</arm_group_label>
    <arm_group_label>Percutaneous Coronary Intervention (PCI)</arm_group_label>
    <other_name>Antiplatelet drugs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PTCA and stents</intervention_name>
    <description>Participants will undergo percutaneous coronary intervention (PTCA) and coronary stenting.</description>
    <arm_group_label>Percutaneous Coronary Intervention (PCI)</arm_group_label>
    <other_name>Percutaneous Transluminal Coronary Angioplasty</other_name>
    <other_name>and</other_name>
    <other_name>Stent Placement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE Inhibitors</intervention_name>
    <description>Participants will receive ACE inhibitors.</description>
    <arm_group_label>Optimal Medical Therapy Only (MED)</arm_group_label>
    <arm_group_label>Percutaneous Coronary Intervention (PCI)</arm_group_label>
    <other_name>angiotensin-converting-enzyme inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recent MI (3-28 days) (Day 1 is the calendar day of the MI system onset)

          -  MI is defined based on at least 2 of 3 MI criteria confirmed by: 1) ischemic symptoms
             ≥30 minutes, 2) cardiac serum marker elevation (creatine kinase (CK) ≥2x upper limit
             of normal and CK-MB elevated above the upper limit of the laboratory normal) or
             troponin T, or troponin I elevated at least twice the upper limit of normal, 3) EKG:
             New Q-waves of ≥0.03 sec and/or 1/3 of QRS complex in ≥2 related EKG leads. If cardiac
             serum markers are elevated (2), any one of the following EKG findings satisfy
             inclusion criteria; new ST-T changes (ST elevation or depression), new left
             bundle-branch block (LBBB), loss of R-wave voltage ≥50% in ≥2 related leads or deep T
             wave inversions ≥3mm in ≥2 leads.

          -  TIMI flow 0 or 1 in infarct related artery (IRA)

          -  Meets criteria for high risk: EF &lt;50% or site of occlusion is proximal, in left
             anterior descending (proximal to the second major diagonal branch); large right
             coronary artery; or circumflex, if supplying large obtuse marginal, and part of
             inferior wall (i.e., large dominant or co-dominant vessel).

        Exclusion Criteria:

          -  Age &lt;18 y

          -  Clinical indication for revascularization defined as follows: rest or low-threshold
             angina after MI; severe inducible ischemia on low level exercise or pharmacological
             stress testing (ST decreased ≥2 mm or inability to complete stage 1 or achieve 3-4
             metabolic equivalents without angina, hypotension, or reversible perfusion defects in
             multiple territories or decreased wall motion thickening in &gt;2 segments on
             echocardiogram); left main coronary disease (≥50% stenosis); or triple-vessel disease
             (3 major epicardial coronaries with &gt;70% stenoses)

          -  Serious illness such as cancer or pulmonary disease that limits 3-year survival

          -  Severe renal disease defined as serum creatinine &gt;3.0 mg/dL that markedly increases
             risk of radiographic contrast

          -  Severe valvular disease

          -  History of anaphylaxis to radiographic contrast

          -  Infarct artery too small (reference segment diameter &lt;2.5 mm), target segment within
             or beyond extreme tortuosity (&gt;90° angulation), or otherwise technically a poor
             candidate for PCI

          -  Chronic occlusion of IRA (seen on angiogram obtained before index MI or angiographic
             evidence of chronicity, e.g., presence of bridging collaterals)

          -  NYHA classes III-IV CHF; patients may be treated for acute heart failure complicating
             MI and rescreened

          -  Cardiogenic shock or sustained hypotension: systolic BP &lt;90 mm Hg or cardiac index
             &lt;2.2 L/min per m^2

          -  LV aneurysm in the same location as index MI and present before index MI

          -  Inability to cooperate with the protocol

          -  Patient refusal or inability to give informed consent

          -  Refusal of patient's physician to allow patient to participate

          -  Pregnancy

          -  Contraindication to anticoagulation during PCI or to routine antiplatelet therapy
             after stent implantation

          -  Qualifying IRA that has been grafted previously; patients with prior CABG may be
             enrolled if the IRA was not previously grafted

          -  Dilated or hypertrophic cardiomyopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith S. Hochman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hochman JS, Lamas GA, Knatterud GL, Buller CE, Dzavik V, Mark DB, Reynolds HR, White HD; Occluded Artery Trial Research Group. Design and methodology of the Occluded Artery Trial (OAT). Am Heart J. 2005 Oct;150(4):627-42.</citation>
    <PMID>16209957</PMID>
  </reference>
  <reference>
    <citation>Skolnick AH, Reynolds HR, White HD, Menon V, Carvalho AC, Maggioni AP, Pearte CA, Gruberg L, Azevedo RE, Schroeder E, Forman SA, Lamas GA, Hochman JS, Džavík V. Comparison of late results of percutaneous coronary intervention among stable patients ≤65 versus &gt;65 years of age with an occluded infarct related artery (from the Occluded Artery Trial). Am J Cardiol. 2012 Mar 1;109(5):614-9. doi: 10.1016/j.amjcard.2011.10.015. Epub 2011 Dec 14.</citation>
    <PMID>22172242</PMID>
  </reference>
  <reference>
    <citation>Deyell MW, Buller CE, Miller LH, Wang TY, Dai D, Lamas GA, Srinivas VS, Hochman JS. Impact of National Clinical Guideline recommendations for revascularization of persistently occluded infarct-related arteries on clinical practice in the United States. Arch Intern Med. 2011 Oct 10;171(18):1636-43. doi: 10.1001/archinternmed.2011.315. Epub 2011 Jul 11.</citation>
    <PMID>21747002</PMID>
  </reference>
  <reference>
    <citation>Udelson JE, Pearte CA, Kimmelstiel CD, Kruk M, Kufera JA, Forman SA, Teresinska A, Bychowiec B, Marin-Neto JA, Höchtl T, Cohen EA, Caramori P, Busz-Papiez B, Adlbrecht C, Sadowski ZP, Ruzyllo W, Kinan DJ, Lamas GA, Hochman JS. The Occluded Artery Trial (OAT) Viability Ancillary Study (OAT-NUC): influence of infarct zone viability on left ventricular remodeling after percutaneous coronary intervention versus optimal medical therapy alone. Am Heart J. 2011 Mar;161(3):611-21. doi: 10.1016/j.ahj.2010.11.020.</citation>
    <PMID>21392619</PMID>
  </reference>
  <reference>
    <citation>Devlin G, Reynolds HR, Mark DB, Rankin JM, Carvalho AC, Vozzi C, Sopko G, Caramori P, Džavík V, Ragosta M, Forman SA, Lamas GA, Hochman JS. Loss of short-term symptomatic benefit in patients with an occluded infarct artery is unrelated to non-protocol revascularization: results from the Occluded Artery Trial (OAT). Am Heart J. 2011 Jan;161(1):84-90. doi: 10.1016/j.ahj.2010.09.009.</citation>
    <PMID>21167338</PMID>
  </reference>
  <reference>
    <citation>Steigen TK, Buller CE, Mancini GB, Jorapur V, Cantor WJ, Rankin JM, Thomas B, Webb JG, Kronsberg SS, Atchison DJ, Lamas GA, Hochman JS, Džavík V. Myocardial perfusion grade after late infarct artery recanalization is associated with global and regional left ventricular function at one year: analysis from the Total Occlusion Study of Canada-2. Circ Cardiovasc Interv. 2010 Dec;3(6):549-55. doi: 10.1161/CIRCINTERVENTIONS.109.918722. Epub 2010 Nov 9.</citation>
    <PMID>21062997</PMID>
  </reference>
  <reference>
    <citation>Jorapur V, Lamas GA, Sadowski ZP, Reynolds HR, Carvalho AC, Buller CE, Rankin JM, Renkin J, Steg PG, White HD, Vozzi C, Balcells E, Ragosta M, Martin CE, Srinivas VS, Wharton Iii WW, Abramsky S, Mon AC, Kronsberg SS, Hochman JS. Renal impairment and heart failure with preserved ejection fraction early post-myocardial infarction. World J Cardiol. 2010 Jan 26;2(1):13-8. doi: 10.4330/wjc.v2.i1.13.</citation>
    <PMID>20885993</PMID>
  </reference>
  <reference>
    <citation>Steg PG, Kerner A, Mancini GB, Reynolds HR, Carvalho AC, Fridrich V, White HD, Forman SA, Lamas GA, Hochman JS, Buller CE; OAT Investigators. Impact of collateral flow to the occluded infarct-related artery on clinical outcomes in patients with recent myocardial infarction: a report from the randomized occluded artery trial. Circulation. 2010 Jun 29;121(25):2724-30. doi: 10.1161/CIRCULATIONAHA.109.933200. Epub 2010 Jun 14.</citation>
    <PMID>20547926</PMID>
  </reference>
  <reference>
    <citation>Kruk M, Buller CE, Tcheng JE, Dzavík V, Menon V, Mancini GB, Forman SA, Kurray P, Busz-Papiez B, Lamas GA, Hochman JS. Impact of left ventricular ejection fraction on clinical outcomes over five years after infarct-related coronary artery recanalization (from the Occluded Artery Trial [OAT]). Am J Cardiol. 2010 Jan 1;105(1):10-6. doi: 10.1016/j.amjcard.2009.08.644.</citation>
    <PMID>20102883</PMID>
  </reference>
  <reference>
    <citation>Buller CE, Rankin JM, Carere RG, Buszman PE, Pfisterer ME, Dzavik V, Thomas B, Forman S, Ruzyllo W, Mancini GB, Michalis LK, Abreu PF, Lamas GA, Hochman JS. Percutaneous coronary intervention in the Occluded Artery Trial: procedural success, hazard, and outcomes over 5 years. Am Heart J. 2009 Sep;158(3):408-15. doi: 10.1016/j.ahj.2009.05.035.</citation>
    <PMID>19699864</PMID>
  </reference>
  <reference>
    <citation>Malek LA, Reynolds HR, Forman SA, Vozzi C, Mancini GB, French JK, Dziarmaga M, Renkin JP, Kochman J, Lamas GA, Hochman JS. Late coronary intervention for totally occluded left anterior descending coronary arteries in stable patients after myocardial infarction: Results from the Occluded Artery Trial (OAT). Am Heart J. 2009 Apr;157(4):724-32. doi: 10.1016/j.ahj.2008.12.008.</citation>
    <PMID>19332202</PMID>
  </reference>
  <reference>
    <citation>Dzavík V, Buller CE, Devlin G, Carere RG, Mancini GB, Cantor WJ, Buszman PE, Rankin JM, Vozzi C, Ross JR, Forman S, Barton BA, Lamas AG, Hochman JS. Angiographic and clinical outcomes of drug-eluting versus bare metal stent deployment in the Occluded Artery Trial. Catheter Cardiovasc Interv. 2009 May 1;73(6):771-9. doi: 10.1002/ccd.21930.</citation>
    <PMID>19309733</PMID>
  </reference>
  <reference>
    <citation>Mark DB, Pan W, Clapp-Channing NE, Anstrom KJ, Ross JR, Fox RS, Devlin GP, Martin CE, Adlbrecht C, Cowper PA, Ray LD, Cohen EA, Lamas GA, Hochman JS; Occluded Artery Trial Investigators. Quality of life after late invasive therapy for occluded arteries. N Engl J Med. 2009 Feb 19;360(8):774-83. doi: 10.1056/NEJMoa0805151.</citation>
    <PMID>19228620</PMID>
  </reference>
  <reference>
    <citation>Kruk M, Kadziela J, Reynolds HR, Forman SA, Sadowski Z, Barton BA, Mark DB, Maggioni AP, Leor J, Webb JG, Kapeliovich M, Marin-Neto JA, White HD, Lamas GA, Hochman JS. Predictors of outcome and the lack of effect of percutaneous coronary intervention across the risk strata in patients with persistent total occlusion after myocardial infarction: Results from the OAT (Occluded Artery Trial) study. JACC Cardiovasc Interv. 2008 Oct;1(5):511-20. doi: 10.1016/j.jcin.2008.08.007.</citation>
    <PMID>19194534</PMID>
  </reference>
  <reference>
    <citation>Rashba EJ, Lamas GA, Couderc JP, Hollist SM, Dzavik V, Ruzyllo W, Fridrich V, Buller CE, Forman SA, Kufera JA, Carvalho AC, Hochman JS; OAT-EP Investigators. Electrophysiological effects of late percutaneous coronary intervention for infarct-related coronary artery occlusion: the Occluded Artery Trial-Electrophysiological Mechanisms (OAT-EP). Circulation. 2009 Feb 17;119(6):779-87. doi: 10.1161/CIRCULATIONAHA.108.808626. Epub 2009 Feb 2.</citation>
    <PMID>19188505</PMID>
  </reference>
  <reference>
    <citation>Menon V, Pearte CA, Buller CE, Steg PG, Forman SA, White HD, Marino PN, Katritsis DG, Caramori P, Lasevitch R, Loboz-Grudzien K, Zurakowski A, Lamas GA, Hochman JS. Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial. Eur Heart J. 2009 Jan;30(2):183-91. doi: 10.1093/eurheartj/ehn486. Epub 2008 Nov 21.</citation>
    <PMID>19028780</PMID>
  </reference>
  <reference>
    <citation>Jorapur V, Steigen TK, Buller CE, Dzavík V, Webb JG, Strauss BH, Yeoh EE, Kurray P, Sokalski L, Machado MC, Kronsberg SS, Lamas GA, Hochman JS, Mancini GB. Distribution and determinants of myocardial perfusion grade following late mechanical recanalization of occluded infarct-related arteries postmyocardial infarction: a report from the occluded artery trial. Catheter Cardiovasc Interv. 2008 Nov 15;72(6):783-9. doi: 10.1002/ccd.21745.</citation>
    <PMID>18798327</PMID>
  </reference>
  <reference>
    <citation>Lamas GA, Hochman JS. Where does the Occluded Artery Trial leave the late open artery hypothesis? Heart. 2007 Nov;93(11):1319-21.</citation>
    <PMID>17933981</PMID>
  </reference>
  <reference>
    <citation>Lang IM, Forman SA, Maggioni AP, Ruzyllo W, Renkin J, Vozzi C, Steg PG, Hernandez-Garcia JM, Zmudka K, Jimenez-Navarro M, Sopko G, Lamas GA, Hochman JS. Causes of death in early MI survivors with persistent infarct artery occlusion: results from the Occluded Artery Trial (OAT). EuroIntervention. 2009 Nov;5(5):610-8.</citation>
    <PMID>20142183</PMID>
  </reference>
  <reference>
    <citation>Cantor WJ, Baptista SB, Srinivas VS, Pearte CA, Menon V, Sadowski Z, Ross JR, Meciar P, Nikolsky E, Forman SA, Lamas GA, Hochman JS. Impact of stress testing before percutaneous coronary intervention or medical management on outcomes of patients with persistent total occlusion after myocardial infarction: analysis from the occluded artery trial. Am Heart J. 2009 Apr;157(4):666-72. doi: 10.1016/j.ahj.2008.12.004. Epub 2009 Feb 23.</citation>
    <PMID>19332193</PMID>
  </reference>
  <reference>
    <citation>Sadanandan S, Buller C, Menon V, Dzavik V, Terrin M, Thompson B, Lamas G, Hochman JS. The late open artery hypothesis--a decade later. Am Heart J. 2001 Sep;142(3):411-21. Review.</citation>
    <PMID>11526353</PMID>
  </reference>
  <reference>
    <citation>Reynolds HR, Forman SA, Tamis-Holland JE, Steg PG, Mark DB, Pearte CA, Carvalho AC, Sopko G, Liu L, Lamas GA, Kruk M, Loboz-Grudzien K, Ruzyllo W, Hochman JS. Relationship of female sex to outcomes after myocardial infarction with persistent total occlusion of the infarct artery: analysis of the Occluded Artery Trial (OAT). Am Heart J. 2012 Mar;163(3):462-9. doi: 10.1016/j.ahj.2012.01.005.</citation>
    <PMID>22424018</PMID>
  </reference>
  <reference>
    <citation>White HD, Reynolds HR, Carvalho AC, Pearte CA, Liu L, Martin CE, Knatterud GL, Džavík V, Kruk M, Steg PG, Cantor WJ, Menon V, Lamas GA, Hochman JS. Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: results from long-term follow-up of the Occluded Artery Trial (OAT) cohort. Am Heart J. 2012 Apr;163(4):563-71. doi: 10.1016/j.ahj.2012.01.016.</citation>
    <PMID>22520521</PMID>
  </reference>
  <reference>
    <citation>Freixa X, Džavík V, Forman SA, Rankin JM, Buller CE, Cantor WJ, Ruzyllo W, Reynolds HR, Lamas GA, Hochman JS. Long-term outcomes after a strategy of percutaneous coronary intervention of the infarct-related artery with drug-eluting stents or bare metal stents vs medical therapy alone in the Occluded Artery Trial (OAT). Am Heart J. 2012 Jun;163(6):1011-8. doi: 10.1016/j.ahj.2012.03.008. Erratum in: Am Heart J. 2013 Apr;165(4):638.</citation>
    <PMID>22709754</PMID>
  </reference>
  <reference>
    <citation>Hastings RS, Hochman JS, Dzavik V, Lamas GA, Forman SA, Schiele F, Michalis LK, Nikas D, Jaroch J, Reynolds HR. Effect of late revascularization of a totally occluded coronary artery after myocardial infarction on mortality rates in patients with renal impairment. Am J Cardiol. 2012 Oct 1;110(7):954-60. doi: 10.1016/j.amjcard.2012.05.024. Epub 2012 Jun 22.</citation>
    <PMID>22728005</PMID>
  </reference>
  <results_reference>
    <citation>Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, Forman S, Ruzyllo W, Maggioni AP, White H, Sadowski Z, Carvalho AC, Rankin JM, Renkin JP, Steg PG, Mascette AM, Sopko G, Pfisterer ME, Leor J, Fridrich V, Mark DB, Knatterud GL; Occluded Artery Trial Investigators. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006 Dec 7;355(23):2395-407. Epub 2006 Nov 14.</citation>
    <PMID>17105759</PMID>
  </results_reference>
  <results_reference>
    <citation>Hochman JS, Reynolds HR, Dzavík V, Buller CE, Ruzyllo W, Sadowski ZP, Maggioni AP, Carvalho AC, Rankin JM, White HD, Goldberg S, Forman SA, Mark DB, Lamas GA; Occluded Artery Trial Investigators. Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction. Circulation. 2011 Nov 22;124(21):2320-8. doi: 10.1161/CIRCULATIONAHA.111.041749. Epub 2011 Oct 24.</citation>
    <PMID>22025606</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2000</study_first_submitted>
  <study_first_submitted_qc>February 9, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2000</study_first_posted>
  <results_first_submitted>May 7, 2010</results_first_submitted>
  <results_first_submitted_qc>January 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2013</results_first_posted>
  <last_update_submitted>April 3, 2014</last_update_submitted>
  <last_update_submitted_qc>April 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Enzyme Inhibitors</mesh_term>
    <mesh_term>Adrenergic Agents</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Adrenergic Antagonists</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The primary analysis of the trial included 2166 patients who had been enrolled through December 2005 with an average follow-up of 2.9 years. An additional 35 patients were enrolled through June 2006 during an extended period of enrollment in the nuclear viability ancillary study. All 2201 patients are included here.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Percutaneous Coronary Intervention Group</title>
          <description>Percutaneous Coronary Intervention with stent placement and optimal medical therapy</description>
        </group>
        <group group_id="P2">
          <title>Medical Therapy Group</title>
          <description>Conventional medical management, including aspirin, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and risk factor modification, plus percutaneous coronary intervention and coronary stenting</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1101"/>
                <participants group_id="P2" count="1100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="999"/>
                <participants group_id="P2" count="1009"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Percutaneous Coronary Intervention Group</title>
          <description>Percutaneous Coronary Intervention with stent placement and optimal medical therapy</description>
        </group>
        <group group_id="B2">
          <title>Medical Therapy Group</title>
          <description>Conventional medical management, including aspirin, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and risk factor modification, plus percutaneous coronary intervention and coronary stenting</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1101"/>
            <count group_id="B2" value="1100"/>
            <count group_id="B3" value="2201"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="10.9"/>
                    <measurement group_id="B2" value="58.7" spread="11.1"/>
                    <measurement group_id="B3" value="58.7" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="242"/>
                    <measurement group_id="B2" value="242"/>
                    <measurement group_id="B3" value="484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="859"/>
                    <measurement group_id="B2" value="858"/>
                    <measurement group_id="B3" value="1717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="888"/>
                    <measurement group_id="B2" value="875"/>
                    <measurement group_id="B3" value="1763"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current cigarette smoker</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Current Cigaratte Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="428"/>
                    <measurement group_id="B2" value="431"/>
                    <measurement group_id="B3" value="859"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="664"/>
                    <measurement group_id="B2" value="660"/>
                    <measurement group_id="B3" value="1324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior History of Characteristics and Risk Factors</title>
          <description>Some study participants had more than one characteristic/risk factor and may be counted more than once.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Angina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="240"/>
                    <measurement group_id="B2" value="255"/>
                    <measurement group_id="B3" value="495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cerebrovascular disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral-vessel disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CABG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                    <measurement group_id="B2" value="251"/>
                    <measurement group_id="B3" value="454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes - Insulin Use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="528"/>
                    <measurement group_id="B2" value="543"/>
                    <measurement group_id="B3" value="1071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Infarct-related artery</title>
          <description>Angiographic characteristic</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Left anterior descending coronary artery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="383"/>
                    <measurement group_id="B2" value="410"/>
                    <measurement group_id="B3" value="793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left circumflex coronary artery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right coronary artery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="541"/>
                    <measurement group_id="B2" value="532"/>
                    <measurement group_id="B3" value="1073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Interval between MI and randomization</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8" lower_limit="5" upper_limit="16"/>
                    <measurement group_id="B2" value="8" lower_limit="5" upper_limit="17"/>
                    <measurement group_id="B3" value="8" lower_limit="5" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients That Had a First Occurrence of the Primary End Point (Composite of Death From Any Cause, Nonfatal MI, or Class IV HF)</title>
        <description>Number of Patients with Events (death from any cause, nonfatal reinfarction, and hospitalization for New York Heart Association (NYHA) Class IV congestive heart failure). Events were centrally adjudicated.</description>
        <time_frame>Measured over a maximum 9-year follow-up period - 6 year median</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention Group</title>
            <description>Percutaneous Coronary Intervention with stent placement and optimal medical therapy</description>
          </group>
          <group group_id="O2">
            <title>Medical Therapy Group</title>
            <description>Conventional medical management, including aspirin, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and risk factor modification, plus percutaneous coronary intervention and coronary stenting</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients That Had a First Occurrence of the Primary End Point (Composite of Death From Any Cause, Nonfatal MI, or Class IV HF)</title>
          <description>Number of Patients with Events (death from any cause, nonfatal reinfarction, and hospitalization for New York Heart Association (NYHA) Class IV congestive heart failure). Events were centrally adjudicated.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1101"/>
                <count group_id="O2" value="1100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230"/>
                    <measurement group_id="O2" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Secondary Outcomes (Safety Events)</title>
        <description>Number of Participants with Secondary Outcomes (death from any cause, nonfatal MI, class IV HF, cardiac death, occurrence of selected clinical outcomes including stroke, hospitalization for CHF, sustained ventricular tachycardia/ventricular fibrillation, ICD implantation, or the composite end point). Events were centrally adjudicated.</description>
        <time_frame>Measured over a maximum 9-year follow-up period - 6 year median</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Percutaneous Coronary Intervention Group</title>
            <description>Percutaneous Coronary Intervention with stent placement and optimal medical therapy</description>
          </group>
          <group group_id="O2">
            <title>Medical Therapy Group</title>
            <description>Conventional medical management, including aspirin, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and risk factor modification, plus percutaneous coronary intervention and coronary stenting</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Secondary Outcomes (Safety Events)</title>
          <description>Number of Participants with Secondary Outcomes (death from any cause, nonfatal MI, class IV HF, cardiac death, occurrence of selected clinical outcomes including stroke, hospitalization for CHF, sustained ventricular tachycardia/ventricular fibrillation, ICD implantation, or the composite end point). Events were centrally adjudicated.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1101"/>
                <count group_id="O2" value="1100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death from all causes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal and nonfatal reinfarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nonfatal reinfarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA class IV heart failure (HF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death or nonfatal reinfarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212"/>
                    <measurement group_id="O2" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA class III or IV HF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death, reinfarction, or NYHA class III or IV HF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249"/>
                    <measurement group_id="O2" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Percutaneous Coronary Intervention Group</title>
          <description>Percutaneous Coronary Intervention with stent placement and optimal medical therapy</description>
        </group>
        <group group_id="E2">
          <title>Medical Therapy Group</title>
          <description>Conventional medical management, including aspirin, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and risk factor modification, plus percutaneous coronary intervention and coronary stenting</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="226" subjects_at_risk="1101"/>
                <counts group_id="E2" subjects_affected="227" subjects_at_risk="1100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death from all causes</sub_title>
                <counts group_id="E1" events="150" subjects_affected="150" subjects_at_risk="1101"/>
                <counts group_id="E2" events="153" subjects_affected="153" subjects_at_risk="1100"/>
              </event>
              <event>
                <sub_title>NYHA class III or IV Heart Failure</sub_title>
                <counts group_id="E1" events="76" subjects_affected="76" subjects_at_risk="1101"/>
                <counts group_id="E2" events="74" subjects_affected="74" subjects_at_risk="1100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="1101"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="1100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Nonfatal reinfarction</sub_title>
                <counts group_id="E1" events="75" subjects_affected="75" subjects_at_risk="1101"/>
                <counts group_id="E2" events="61" subjects_affected="61" subjects_at_risk="1100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The NIH Public Access Policy ensures that the public has access to the published results of NIH funded research. It requires scientists to submit final peer-reviewed journal manuscripts that arise from NIH funds to the digital archive PubMed Central upon acceptance for publication. To help advance science and improve human health, the Policy requires that these papers are accessible to the public on PubMed Central no later than 12 months after publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Judith S. Hochman, M.D.</name_or_title>
      <organization>New York University School of Medicine</organization>
      <phone>212-263-6927</phone>
      <email>judith.hochman@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

